Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-24 @ 5:52 PM
Ignite Modification Date: 2025-12-24 @ 5:52 PM
NCT ID: NCT03574168
Eligibility Criteria: Inclusion Criteria: 1. Obtain Informed Consent Form (ICF) voluntarily signed by the patient; 2. Age 3-70 years old; 3. Primary resistant or relapsed B-cell line acute lymphoblastic leukemia; 4. B cells are positive for CD19 expression; 5. Peripheral blood tumor cell load \<50%; 6. KPS score \>50 points; 7\. Normal liver and kidney function; 8. Normal heart function; 9. Good follow-up compliance; 10. Women of childbearing age (15-49 years old) must have a pregnancy test within 7 days before treatment and have a negative result; Men and women with fertility should agree to use effective contraception to ensure that during the study period and following 3 months after treatment the women will not get pregnant. Exclusion Criteria: 1. Patients with non-B cell acute leukemia; 2. Organ failure: Heart: Grade III and IV Liver: Class C with Child-Turcotte liver function classification Kidney: Renal failure and uremia Lung: severe respiratory failure Brain: Disabilities 3. Active infection; 4. Human immunodeficiency virus (HIV) positive; 5. Acute and chronic graft-versus-host disease (GVHD)\> Level 1; 6. Pregnant or lactating women; 7. Patients do not agree to use effective contraception during the treatment period and following 3 months; 8. Patients who participated in other clinical studies at the same time; 9. The researcher believes that there are other factors that are not suitable for inclusion in or influence the subject's participation in or completion of the study; 10. Long-term use greater doses of hormones than physiological doses.
Healthy Volunteers: False
Sex: ALL
Minimum Age: 3 Years
Maximum Age: 70 Years
Study: NCT03574168
Study Brief:
Protocol Section: NCT03574168